Alcon (ALC) Q2 FY25 earnings call: guidance and Q&A

Can you elaborate on the stabilization of U.S. PC-IOL share with PanOptix Pro and comment on AT-IOL share outside the U.S.?

U.S. PC-IOL share improved sequentially by about 4 points in Q2, attributed to PanOptix Pro's reception and a competitive outage. International markets, particularly Europe, experienced pressure and some share loss due to new competitor products, with the IOL space expected to remain competitive globally for the next 18-24 months.

“the second quarter for us was sequentially better by about 4 share points. It was -- I think, obviously, PanOptix Pro has been well received for all the reasons I mentioned in the remarks, and I'm pleased with the way it's performing right now.”

asked by Jeff Johnson · answered by David Endicott

How should we conceptually set up models for 2026 given recent deals, new product launches, and tariff pressures, and can next year be a good earnings growth year?

Management expressed confidence in recent deals adding long-term strategic value, noting that the STAAR acquisition's impact on 2026 will depend on its closing timeline (6-12 months). They highlighted Alcon's global footprint and shared services for leveraging synergies, but declined to provide specific 2026 guidance at this time.

“we feel great about the deals that we've done. We feel like they add long-term strategic value. Keep in mind, the biggest deal obviously being STAAR. That doesn't close for 6 to 12 months. So that's probably going to have limited impact on next year, but it depends on when we close the deal.”

asked by Jeff Johnson · answered by Timothy Stonesifer

What is driving the current market weakness, and what gives you confidence in its return to historical growth rates, including a timeframe?

The market weakness, particularly in surgical procedure volumes (low single digits vs. historical 4%), is viewed as a 'normal oscillation' within the historical range. Management is confident in long-term fundamentals due to the aging population and increasing cataract prevalence, expecting a reversion to the mean, but will monitor for a couple more quarters before providing further guidance for next year.

“there aren't fewer cataracts today or tomorrow, there's going to be only an increasing number. And if you look at our procedural volumes, that's what gives us confidence around the treatment in the end.”

asked by Jack Reynolds-Clark · answered by David Endicott

Can you provide more color on the Unity VCS order book, line of sight for placements, and recent placement activity in July and August?

Since its late May launch, Unity VCS has accumulated over 1,000 qualified leads in about 10 weeks. The launch is deliberate and ramped, focusing on training and support, especially for retina specialists, due to the system's complexity. Management is comfortable with the current pace and expects the ramp to continue building, aiming to replace the 30,000-unit installed base over the next decade.

“in that 10 weeks, we've accumulated over 1,000 kind of qualified or quoted or contracted leads. So our funnel is very solid at this point.”

asked by Jack Reynolds-Clark · answered by David Endicott

How important is the China market to the STAAR acquisition, and what are your views on local competition in the ICL space there?

China is important but not the sole long-term driver for the STAAR acquisition, as the myopia epidemic is a global opportunity. Alcon's critical mass and combined offering (EVO for high myopes and Lasik for lower diopters) will make it highly competitive against local players and enable expansion into other markets, providing a comprehensive refractive solution.

“Although I would say China matters a lot, it's not the long term. I mean long term for us, we'll be there. We're going to be -- it's going to be a huge market for us, and we'll be there with both above 6 diopters for EVO and Lasik for below 6 after.”

asked by Anthony Petrone · answered by David Endicott

Why is Alcon's tariff headwind forecast increasing while other companies' are decreasing, and what is the mitigation strategy?

The increased tariff headwind is primarily due to EU tariffs coming in at 15%, higher than the 10% previously anticipated in May. Mitigation efforts are largely driven by the strong U.S. dollar and other foreign exchange benefits. The company is also evaluating manufacturing footprint changes for long-term stability, but larger moves require a more stable policy environment.

“if you think about the EU as an example, coming in at 15%, I think what we had at the May time frame, folks were talking about the 10% kind of range. So I would say that's one of the key drivers of it.”

asked by Christopher Pasquale · answered by Timothy Stonesifer

How do current market growth rates impact the long-term targets of 5% market growth plus 200 bps innovation for 7% total growth?

Management reiterated confidence in long-term targets, viewing the current surgical market softness (low single digits vs. historical 4%) as a temporary oscillation. They highlighted healthy growth in contact lens (mid-single to high-single digits) and OTC eye drops (4-5%), along with numerous new product launches and acquisitions, as drivers that support the long-term growth algorithm.

“I don't think we feel any differently about the long term. Obviously, we've called the market off 3 times now. So I mean we missed the surgical market. That's just a fact.”

asked by Ryan Zimmerman · answered by David Endicott